Roberta Duncan is the Chief Strategy Officer at Arcturus Therapeutics and has been in the biopharma industry for more than 26 years with experience from start-up and small biotech to pharma and CROs. She is currently the Board Vice-Chair of the Alliance for mRNA Medicines (AMM) and previously held the role of Vice President leading CSL’s enterprise-wide mRNA Program. Roberta has led complex programs, driving profitable growth, enhancing productivity, accelerating critical growth assets into the pipeline, leading revenue generating products, and enabling commercial launch and market expansion. Roberta has an extensive and diverse background across multiple therapeutic areas and business functions, inclusive of strategy, business development, business planning and operations, governance, portfolio and program management, program leadership, alliance management, R&D (including clinical development, regulatory, clinical operations, R&D systems and compliance), and product development. Her experience spans across industry-leading organizations such as CSL, Eli Lilly, Bristol Myers Squibb, Shire Pharmaceuticals (acquired by Takeda), Trevi Therapeutics, Kendle International (acquired by Syneos), and Quintiles (now IQVIA).

Roberta earned her BA in Biochemistry from New York University, as well as two MBAs in International Management and Strategy from Krannert School of Management (Purdue University) and TiasNimbas Business School (Tilburg University, The Netherlands).